复发性脑肿瘤再程放疗:ESTRO CNS 焦点组综述
欧洲放射肿瘤学会中枢神经焦点组对脑膜瘤、室管膜瘤、脑转移瘤和垂体神经内分泌肿瘤的再程放疗证据进行非系统性综述,排除胶质瘤。再程放疗在精心选择的患者中显示潜在疗效与安全性,但现有研究多为回顾性、报告不统一且异质性大,需前瞻性研究。
要点
- 再程放疗需综合既往治疗、分次方案、危及器官剂量、影像、复发体积及间隔时间选择患者。
- 现有证据多为回顾性研究,报告缺乏标准化且队列与治疗异质性大。
- 不同肿瘤实体的再程放疗研究提示精心选择患者中潜在有效且安全。
核心结论
- 不同肿瘤实体的再程放疗研究提示在精心选择的患者中具有潜在疗效与安全性。
- 现有研究存在重要局限性,需设计良好且报告严谨的前瞻性研究。
研究设计与样本
- 欧洲放射肿瘤学会中枢神经焦点组开展的非系统性综述,排除胶质瘤。
- 综述脑膜瘤、室管膜瘤、脑转移瘤、垂体神经内分泌肿瘤再程放疗及放射性坏死管理的相关研究。
主要发现
- 再程放疗在原发性和继发性脑肿瘤中应用的成功程度不一。
- 再程放疗的适当使用需考虑既往治疗疗程、分次方案、危及器官剂量、影像表现、复发肿瘤体积及距前次治疗间隔等因素。
- 绝大多数可用研究受限于回顾性设计、报告缺乏标准化以及队列和治疗间的整体异质性。
临床怎么用
- 再程放疗应基于既往治疗、分次方案、危及器官剂量、影像、复发体积和间隔时间等因素综合选择患者。
局限性
- 现有研究多为回顾性设计,报告缺乏标准化,队列与治疗异质性大。
- 需设计良好、报告严谨的前瞻性研究验证原发性和继发性脑肿瘤的再程放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reirradiation has become an area of increasing clinical and scientific interest, particularly in neuro-oncology. This non-systematic review on central nervous system (CNS) tumors by the CNS focus group of the European Society for Radiotherapy and Oncology provides a pragmatic synthesis of the available evidence, excluding gliomas. We address key questions related to patient selection, fractionation, technical considerations, and treatment safety. METHODS: Relevant studies on the use of reirradiation for meningiomas, ependymomas, brain metastases, and pituitary neuroendocrine tumors, as well as on the management of radiation necrosis, have been reviewed and summarized. RESULTS: Reirradiation has been used with varying success in primary and secondary brain tumors. The appropriate use of reirradiation requires consideration of numerous factors, including, but not limited to, prior treatment courses, fractionation, dose to organs at risk, imaging findings, the volume of the recurrent tumor, and the interval since prior treatments. The vast majority of available studies are limited by their retrospective design, lack of standardization in reporting, and overall heterogeneity across cohorts and treatments. CONCLUSION: Several reirradiation studies across different tumor entities suggest potential efficacy and safety in carefully selected patients. However, important limitations remain, underscoring the need for well-designed prospective studies with rigorous reporting in both primary and secondary brain tumors.
引用
- De Pietro R, Clerici E, Harat M, et al. Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group. Clin Transl Radiat Oncol. 2026. PMID: 42835612. doi:10.1016/j.ctro.2026.101260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。